simurosertib
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2016 (NCT02699749)
Timeline
Indications
Mechanism of action
CDC7 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1n[nH]cc1-c1cc2nc([C@@H]3CC4CCN3CC4)[nH]c(=O)c2s1- Mol. weight
- 341.44 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297644 ↗
Also known as
- tak-931
- tak-931
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03708211 | Phase 1 | Mar 28, 2019 | Millennium Pharmaceuticals |
| NCT03261947 | Phase 2 | Oct 25, 2017 | Millennium Pharmaceuticals, Takeda |
| NCT02699749 | Phase 1 | Mar 1, 2016 | Millennium Pharmaceuticals |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Millennium Pharmaceuticals | For profit | 3 | 3 | 2 | 2016 |
| Takeda | For profit | 1 | 0 | 1 | 2017 |
2 organizations
Page 1 / 1